BYON4228: A phase 1 trial of BYON4228 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

This trial is testing the medication BYON4228 in adults with B-cell non-Hodgkin lymphoma (NHL) which has returned after (relapsed) or not responded to (refractory) treatment. 

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05737628

Trial aim and background

The aim of this phase 1 trial is to investigate the medication BYON4228 which is a humanized monoclonal antibody (mAB). It will firstly look at the best dose of the medication and will then look at how safe and effective it is.

This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter

Patients with diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) or follicular lymphoma (FL) which has not responded to two previous treatments may be eligible for this trial.

Locations 

Recruitment is taking place in the following UK locations:

  • The Christie NHS Foundation Trust, Manchester
  • Derriford Hospital, Plymouth

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05737628

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.